Cargando...
Oligonucleotide therapeutics in neurodegenerative diseases
Therapeutics that directly target RNAs are promising for a broad spectrum of disorders, including the neurodegenerative diseases. This is exemplified by the FDA approval of Nusinersen, an antisense oligonucleotide (ASO) therapeutic for spinal muscular atrophy (SMA). RNA targeting therapeutics are cu...
Gardado en:
| Publicado en: | RNA Biol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Taylor & Francis
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6152438/ https://ncbi.nlm.nih.gov/pubmed/29560813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15476286.2018.1454812 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|